Metformin to Augment Low Milk Supply (MALMS) Study
Low Milk Supply · Pre-diabetes · Insulin Resistance · Suppressed Lactation
Bottom Line
View on ClinicalTrials.gov: NCT02179788 ↗Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Standard care (Behavioral); Metformin (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- Female
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Primary completion
- Jul 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Peak Change in Milk Output |
8; -58 | — |
Summary
Eligibility Criteria
Inclusion Criteria among mother-infant dyads:
Stage 1 Criteria (for participation in baseline measurement phase):
- identified with low milk supply by a Cincinnati-area IBCLC
- mother denies obvious cause of low milk supply such as pituitary disorder, breast surgery, severe lack of breast emptying ( 37 weeks gestation) infant
- mother free of breast and nipple infections
- mother lives within study catchment area
- mother has not been diagnosed with Type 1 or Type 2 Diabetes Mellitus
- mother willing to sustain consistent use of herbal galactogogues (such as fenugreek) during follow up measurements (2-4 weeks) as was consumed during the baseline measurements
- mother not currently taking a prescription medication that may affect the hormones of lactation and not planning to initiate any such drug for at least the next 2-4 weeks.
- mother has established pediatric care for the infant
Stage 2 maternal inclusion criteria (among those who meet Stage 1 criteria, to continue with enrollment into randomized controlled trial, goal, N=30 with replacement for non-completers to at least two weeks):
- successful completion of baseline measurements (involving 24-hour test weighing of milk output and undergoing baseline measurements at the clinical research center, including providing fasting blood samples)
- body mass index is >19.0 kg/m2 (i.e., not underweight)
- evidence of likely insulin resistance, based on at least one of the following: mean fasting plasma glucose between 95.0 - 125.0 g/dL, inclusive; abdominal obesity; history of polycystic ovary syndrome; or history of gestational diabetes
- estimated glomerular filtration rate > 60 mL/min
- liver function in normal range (AST <= 37 U/L, ALT < 87 U/L, and total bilirubin <= 1.1 mg/dL
- willingness to continue trying to lactate for the next 2-4 weeks
- health history does not reveal illness/treatments for which metformin is contraindicated
- participant is not currently being treated with metformin
Eligibility criteria for enrollment into abundant milk supply comparison group (goal, N=30, will be compared in baseline measurements).
Inclusion criteria
- exclusively feeding mother's own milk to infant, and presenting to Cincinnati area IBCLC with breastfeeding question or problem unrelated to milk supply
- mother at least 20 years of age
- infant is between 1 week and 2 calendar months old
- mother gave birth to a single, term infant
- mother free of breast and nipple infections
- mother lives within study catchment area
- mother has not been diagnosed with Type 1 or Type 2 Diabetes Mellitus
- mother willing to sustain consistent use of herbal galactogogues (such as fenugreek) during baseline measurements
- mother willing to avoid prescription medication that may affect the hormones of lactation
Data sourced from ClinicalTrials.gov (NCT02179788). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.